The transcription factor NF-kB has anti-apoptotic properties and may confer chemoresistance to cancer cells. Here, we describe human pancreatic carcinoma cell lines that dier in the responsiveness to the topoisomerase-2 inhibitors VP16 (20 mM) and doxorubicin (0.3 mM): Highly sensitive BxPC-3 and PT45-P1 cells, and Capan-1 and A818-4 cells that were almost resistant to both anti cancer drugs. VP16, but not doxorubicin, transiently induced NF-kB activity in all cell lines, whereas basal NF-kB binding was nearly undetectable in BxPc-3 and PT45-P1 cells, but rather high in Capan-1 and A818-4 cells, as demonstrated by gel-shift and luciferase assays. Treatment with various NF-kB inhibitors (Gliotoxin, MG132 and Sulfasalazine), or transfection with the IkBa super-repressor, strongly enhanced the apoptotic eects of VP16 or doxorubicin on resistant Capan-1 and 818-4 cells. Our results indicate that under certain conditions the resistance of pancreatic carcinoma cells to chemotherapy is due to their constitutive NF-kB activity rather than the transient induction of NF-kB by some anti-cancer drugs. Blockade of basal NF-kB activity by well established drugs eciently reduces chemoresistance of pancreatic cancer cells and oers the potential for improved therapeutic strategies. Oncogene (2001) 20, 859 ± 868.
Introduction
Cell viability is a tightly regulated process under control of numerous signal transduction pathways. Amongst these, the transcription factor NF-kB has gained much attention. NF-kB exists as homo-or heterodimer, composed of proteins of the Rel family ± typically p50/p50 and p50/p65, respectively. Meanwhile, it has been demonstrated that NF-kB-inducible genes are implicated in the control of apoptosis, i.e. members of the TRAF, c-IAP or Bcl gene families (reviewed in Barkett and Gilmore, 1999) . Blockade of NF-kB activation triggers apoptosis in several cell types and, in turn, exaggerated NF-kB recruitment has been shown to prevent apoptosis (Liu et al., 1996; Krappmann et al., 1999; Zong et al., 1998 ) ± a condition that might favor the development and progression of cancer.
The rational of anti-cancer chemotherapy mainly relies on DNA-damaging insults in rapidly dividing tumor cells, imposing a strong apoptotic trigger. Common therapeutic strategies focus on agents that interchelate with or modify genomic DNA. The phyllotoxin analogue VP16 (etoposide) and the anthracycline analogue doxorubicin which both induce DNA double-strand breaks by interfering with the actions of topoisomerase II-a (Kingma and Oshero, 1998) have gained broad application for chemotherapy of several malignant tumors (Fry et al., 1991) . However, resistance to apoptosis severely limits the ecacy of many anti-cancer drugs, including certain types of tumors that do not respond to the cytotoxic eect of VP16 and doxorubicin (Dingemans et al., 1999; Long et al., 1991) . These tumors exhibit various alterations in their genetic repertoir of growth control and apoptosis, including the functional loss of p53 (Lam et al., 1999) and mutations in the topoIIa gene (Dingemans et al., 1999; Mao et al., 1999) . Another mechanism by which tumor cells may have gained resistance to cytotoxic drugs includes the activation of NF-kB (Jeremias et al., 1998; McDade et al., 1999) , a condition that has been recently reported for some pancreatic carcinoma cells (Wang et al., 1999a) . Still, a close functional relation of the NF-kB status in pancreatic carcinoma cells and their resistance to chemotherapy remains to be investigated.
In the present study, we elucidated the sensitivity of a variety of human pancreatic carcinoma cell lines to VP16 and doxorubicin and examined the involvement of NF-kB in those molecular mechanisms confering resistance to DNA-damage induced apoptosis.
Results

Sensitivity of human pancreatic cancer cell lines to VP16 and doxorubicin
The pancreatic carcinoma cell lines BxPc-3, PT45-P1, Capan-1 and A818-4 were exposed to VP16 (20 mM) and doxorubicin (0.3 mM) for 24 h ± both well established conditions to eciently induce apoptosis. As shown in Figure 1 , BxPc-3 and PT45-P1 cells exhibited a strong increase of apoptosis indicated by their intensive annexinV staining (62% and 49% of total cell count) compared to untreated cells (14% and 12%). By contrast, apoptosis of Capan-1 and A818-4 cells did not increase signi®cantly upon VP16 treatment (25% and 19%, respectively) compared to untreated cells (20% and 16%, respectively). Similar results were obtained when analysing doxorubicin treated cells, as shown in Figure 1 . Again, BxPc-3 and PT45-P1 cells were highly positive for annexinV staining (67% and 61%, respectively) upon administration of doxorubicin, whereas Capan-1 and A818-4 cells exhibited only a slight increase in the number of apoptotic cells (22% and 23%, respectively).
Inducible and basal NF-kB activity in pancreatic carcinoma cells
To elucidate whether treatment with chemotherapeutic drugs induces NF-kB activity, gel-shift assays were conducted. As shown in Figure 2a , nuclear extracts from BxPC-3 and PT45-P1 cells contained high levels of NF-kB binding activity upon 1 ± 3 h treatment with VP16, whereas extracts from untreated BxPC-3 and PT45-P1 cells or from cells incubated with VP16 for extended periods (6 or 24 h) did not contain signi®cant NF-kB binding activity. In nuclear extracts from Capan-1 and A818-4 cells, strong NF-kB binding was present even in untreated cells, and upon VP16 treatment the increase of NFkB binding activity, if any, continued at least up to 24 h. The speci®city of the detected DNA-protein complexes was demonstrated by supershift assays identifying both p65/p50 heterodimers and p50/p50 homodimers (Figure 2b ). Compared to the strong dierence of basal NF-kB activity in Capan-1 and A818-4 cells on the one hand, and in BxPc-3 and PT45-P1 cells on the other, the binding activity of another transcription factor, here AP-1, did not dier in all four cell lines (Figure 2c ). Interestingly, doxorubicin at 0.3 mM did not induce NF-kB binding activity in all cell lines (data not shown). This is supported by recent ®ndings that doxorubicin at a dose below 10 mM is not eective in NF-kB activation (Das et al., 1998) .
The dierent levels of constitutive NF-kB activity were also veri®ed by luciferase assays. For this purpose, cells were transiently transfected with either an NF-kB or an AP-1 driven luciferase expression vector. As shown in Figure 3a , in untreated Capan-1 and A818-4 cells NF-kB-dependent expression of luciferase was ten and fourfold higher, respectively, compared to BxPc-3 and PT45-P1 cells. In contrast, basal luciferase expression driven by AP-1 was similar in all cell lines tested. Upon VP16 treatment for 6 h, NF-kB-induced luciferase expression in Capan-1 and A818-4 cells was signi®cantly higher compared to BxPc-3 and PT45-P1 cells. By contrast, in all cell lines VP16 only moderately induced AP-1 dependent expression of luciferase (Figure 3a ).
Pharmacological inhibition of inducible and basal NF-kB activity
The NF-kB inhibitors gliotoxin (0.5 mM), MG132 (10 mM) and sulfazalazine (0.5 mM) which interfere with NF-kB activation at distinct levels (Pahl et al., 1996; Hellerbrand et al., 1998; Wahl et al., 1998) were used for pharmacological blockade of NF-kB activity. The interferences of these inhibitors with NF-kB activation could be veri®ed on the level of NF-kB-dependent luciferase expression (Figure 3a) . In all cell lines, gliotoxin, MG132 or sulfasalazine strongly reduced VP16-induced NF-kB-driven luciferase expression. Additionally, in Capan-1 and A818-4 cells, the high basal NF-kB-dependent luciferase expression was almost completely blocked. Again, AP-1 driven reporter gene expression was only marginally aected. As further shown by gel-shift assays (Figure 3b ), gliotoxin, MG132 or sulfasalazine strongly reduced the intensities of the labeled NF-kB complexes upon VP16 treatment. In Capan-1 and A818-4 cells, the inhibitors reduced the NF-kB activity even below the basal level. In contrast, no such reducing eect of the inhibitors was observed if gel-shift assays for AP-1 were carried out (data not shown). Pharmacological inhibition of NF-kB attenuates the resistance to VP16 and doxorubicin In A818-4 and Capan-1 cells, the moderate apoptotic eect of VP16 (25% and 21% annexinV positive cells, respectively) was strongly enhanced in the presence of gliotoxin (65 and 69%), MG132 (64 and 79%) and sulfasalazine (61 and 62%). By contrast, in BxPc-3 and PT45-P1 cells, the eect of VP16 on apoptotic cell number was only moderately enhanced by gliotoxin and MG132, or even slightly reduced by sulfasalazine ( Figure 4a ). Administration of gliotoxin or MG132 alone, which themselves possess some cytotoxic potential, caused only a moderate increase of apoptosis (10 ± 15%) in all cell lines, and sulfasalazine alone ± at least at the dose used in this study ± did not aect the viability of the cells, at all (data not shown).
Although doxorubicin at the present dose (0.3 mM) did not induce NF-kB binding activity, NF-kB inhibitors also rendered A818-4 and Capan-1 cells being more sensitive to doxorubicin induced cytotoxicity ( Figure 4b ). In the presence of gliotoxin, MG132 and sulfasalazine the number of annexinV positive cells Figure 2 NF-kB binding activity prior to and during treatment with VP16. BxPc-3, PT45-P1, Capan-1 and A818-4 cells were exposed to VP16 (20 mM) for various periods. (a) At the indicated time nuclear protein was prepared for gel-shift assays performed with a 32 P-labeled NF-kB consensus oligonucleotides as probe. Nuclear extracts from untreated cells were submitted to: (b) supershift assays with monoclonal antibodies against p65 and p50 or against AP-1 as control; or to (c) gel-shift assays performed with 32 P-labeled NF-kB or AP-1 consensus oligonucleotides. Representative results from three independent experiments are shown upon doxorubicin administration alone (15 and 20%) increased to 57 ± 82%. In BxPc-3 and PT45-P1 cells, the cytotoxic eect of doxorubicin alone was again moderately increased by gliotoxin as well as by MG132 or slightly reduced by sulfasalazine.
Western blot analysis of caspase mediated cleavage of Poly (ADP Ribose) Polymerase (PARP) con®rmed the sensitizing eect of NF-kB inhibitors in A818-4 and Capan-1 cells. As shown in Figure 4c and 4d, no cleavage of PARP occurred in Capan-1 and A818-4 cells if incubated for 24 h with VP16 or doxorubicin alone, instead the level of the intact protein (115 kDa) remained unchanged. By contrast, in BxPc-3 and PT45-P1 cells the 86 kDa cleavage product of PARP was readily detectable within 24 h, whereas the level of the intact protein slightly decreased. Upon the addition of MG132, which itself did not induce PARP degradation (data not shown), signi®cant cleavage of PARP occurred in Capan-1 and A818-4 cells in response to both anti-cancer drugs, as indicated by the appearance of the 86 kDa protein. In BxPC-3 and PT45-P1 cells, PARP degradation induced by VP16 or doxorubicin was enhanced by MG132. An increase of anti-cancer drug induced PARP cleavage was also noted in the presence of gliotoxin and sulfasalazine (data not shown). Under these conditions, Capan-1 and A818-4 cells revealed an increased rate of apoptosis ( Figure 6 ). If transfected with DN-IkBa, 42 and 55% of Capan-1 and A818-4 cells became apoptotic in response to VP16, whereas mock-transfected cells were much less sensitive (14 and 18% apoptotic cells, respectively). In a similar fashion, the sensitivity of Capan-1 and A818-4 cells to doxorubicin was strongly increased from 18 and 19% apoptotic cells (mock-transfected), respectively, to 38 and 36%, respectively, if transfected with DN-IkBa. Interestingly, Capan-1 cells, and to a lesser extent A818-4 cells, were highly sensitive to Fas-induced (100 ng/ml agonistic antibody CH11) apoptosis even in the absence of DN-IkBa (56 and 38% apoptotic cells, respectively) and exhibited only a moderate increase in Fas-dependent cell death (61 and 66%, respectively) upon transfection with the IkBa superrepressor.
Time dependent IL-1b-inducible chemoresistance in PT45-P1 or BxPC3 cells
In order to overcome the sensitivity of PT45-P1 and BxPc-3 involving NF-kB activation, both cell lines were treated with IL-1b prior, during or after administration of VP16 or doxorubicin. As shown in Figure 7a , upon anti-cancer drug administration neither the preincubation for 2 h, nor the simultaneous or slightly delayed (2 and 4 h) addition of IL1b (0.5 ng/ml), nor its late addition (20 h) in¯uenced the apoptotic response to VP16 (upper panel) or doxorubicin (lower panel) observed after 28 h. In contrast, during a period between 8 and 14 h upon drug administration the addition of IL-1b signi®cantly decreased the rate of apoptosis induced by VP16 (upper panel). At these time points, both cell lines incubated with IL-1b exhibited a decline of the apoptotic cell number (29 and 30% apoptotic PT45-P1 cells, and 31 and 34% apoptotic BxPC-3 cells, respectively) compared to cells without IL1b treatment (45 and 47%, respectively). A similar eect was observed at 8 and 14 h upon doxorubicin administration. IL-1b reduced the number of apoptotic PT45-P1 (36 and 31%) and BxPc-3 cells (41 and 37%) compared to cells without IL-1b treatment (48% apoptotic PT45-P1 cells, and 59% apoptotic BxPc-3 cells). At both time points upon VP16 administration, IL-1b induced NF-kB, as demonstrated by gel-shift assay (Figure 7b ). The desensitizing eect of IL-1b in BxPC-3 and PT45-P1 cells was abolished in the presence of the IkBa super-repressor (Figure 7c ). Compared to lacZ transfected cells, DN-IkBa transfectants, exhibited no decrease of VP16 or doxorubicin induced apoptosis if IL-1b was added 8 h upon drug administration. Instead, apoptosis slightly increased in DN-IkBa transfectants.
Discussion
One major obstacle for chemotherapy emerges if tumor cells become resistant to DNA damage. In the present study, we elucidated to what extent the activity of the NF-kB transcription factor contributes to the resistance of pancreatic cancer cells to VP16 or doxorubicin induced apoptosis. Amongst four cell lines originated from ductal pancreatic adenocarcinoma, two cell lines, PT45-P1 displaying a poorly and BxPc-3 cells displaying a moderately dierentiated phenotype (Egawa et al., 1996; Mazo et al., 1991) , turned out to be highly susceptible to treatment with VP16 or doxorubicin. By contrast, moderately dierentiated Capan-1 and highly dierentiated A818-4 cells (Egawa et al., 1996; Estival et al., 1992) were much less sensitive or almost resistant to treatment with VP16 or doxorubicin. Since all cell lines express comparable levels of topoisomerase-2-a (results not Figure 6 Resistance to VP16 and doxorubicin is inhibited in Capan-1 and A818-4 cells expressing the IkBa super-repressor. Capan-1 and A818-4 cells were transiently transfected with an expression vector for DN-IkBa or lacZ (mock). Transfectants were exposed to VP16 (20 mM), doxorubicin (0.3 mM) or an agonistic Fas antibody (CH11, 100 ng/ml) and cell death was determined by the FITC-annexinV/PI apoptosis assay. Data represent the mean+s.d., n=6
shown) the distinct responses to VP16 and doxorubicin were not due to the absence or presence of topo-2-a. Similarly, the lack of sensitivity to the anticancer drugs seems to be independent of p53, since all four pancreatic cell lines harbor mutations in this tumor suppressor (Kaltho et al., 1993; H Schmale, Hamburg, personal communication) .
One mechanism by which Capan-1 and A818-4 cells are able to survive VP16 and doxorubicin induced DNA damage seems to be related to their elevated levels of basal NF-kB activity. Administration of agents that inhibit NF-kB activation like gliotoxin, MG-132 or sulfasalazine (Pahl et al., 1996; Hellerbrand et al., 1998; Wahl et al., 1998) , or ectopic expression of an IkBa-super-repressor, strongly triggered apoptosis of Capan-1 and A818-4 cells in response to anti-cancer drug treatment, making them similar or even more sensitive compared to BxPc-3 and PT45-P1 cells.
Irrespective of their chemosensitivity, all cell lines exhibit VP16 inducible NF-kB activity, whereas doxorubicin at death inducing concentrations was without eect on NF-kB (Das et al., 1998) even though inhibition of constitutive NF-kB activity renders Capan-1 and A818-4 cells being more sensitive to doxorubicin, as well. Obviously, the resistance to both anti-cancer drugs is dispensable from transient activation of NF-kB, but indispensable from the persistent NF-kB activity seen in Capan-1 and A818-4 cells. This observation is compatible with the idea that the extent of constitutive NF-kB activity rather than its transient induction (if any) is responsible for the distinct responsiveness of these cells to VP16 and doxorubicin. In support of recent ®ndings demonstrating distinct NF-kB levels in various pancreatic carcinoma cell lines (Wang et al., 1999a) , untreated Capan-1 and A818-4 cells exhibited considerably higher basal NF-kB activities, whereas untreated BxPc-3 and PT45-P1 lack signi®cant basal NF-kB activity. In addition, upon treatment with VP16 the rapid gain of NF-kB activity observed in all cell lines was followed by a sustained elevation in Capan-1 and A818-4 cells but not in BxPc-3 and PT45-P1 cells.
Both sensitive cell lines could be signi®cantly rescued from anti-cancer drug induced apoptosis, if NF-kB activity was elevated by the addition of IL-1b. This cytokine is supposed to be involved into para-or autocrine mechanisms protecting certain tumors from apoptosis in an NF-kB-dependent fashion (KothnyWilkes et al., 1998) . This includes pancreatic carcinoma cell lines, i.e. A818-4 cells, that produce a secretory activity conferring chemoresistance in PT45-P1 or BxPc-3 cells and being blocked by an antagonistic IL-1 receptor antibody (results not shown). In agreement with this observation, IL-1b reduced VP16-and doxorubicin-induced apoptosis in PT45-P1 and BxPc-3 cells (Figure 7 ). This protective eect was restricted to a period of 8 ± 14 h after anti-cancer drug administration and obviously requires NF-kB activity as IL-1b did not decrease drug induced cell death in the presence of the IkBa super-repressor. Since during this period DNA-repair mechanisms and/or the initiation of cell cycle arrest and apoptosis may take place, the protection by NF-kB seems to be most eective in this context. Interestingly, the IL-1b eect was prominent in BxPc-3 and PT45-P1 during a period where NF-kB levels upon VP16-treatment already returned to basal levels.
As the chemosensitive BxPc-3 and PT45-P1 cells could be discriminated from chemoresistant Capan-1 and A818-4 cells by their apparent lack of basal and sustained NF-kB activity, it can be assumed that distinct cellular responses exist that require persistent rather than transient NF-kB activity. The observation ( Figure 6 ) that in Capan-1 and A818-4 cells Fas activation induces cell death suggests that the constitutive NF-kB activity in these cells protects from apoptosis induced by anti-cancer drugs, but not from apoptosis initiated by death receptors (Ungefroren et al., 1998) . In turn, the resistance to Fas (results not shown) exhibited by BxPc-3 and PT45-P1 (Ungefroren et al., 1998) , is in sharp contrast to the sensitivity to VP16. Nevertheless, NF-kB blockade renders both types of cells being less resistant to either type of apoptotic trigger: VP16 or doxorubicin in Capan-1 or A818-4 cells, and Fas in BxPc-3 or PT45-P1 cells. Obviously, NF-kB dependent repression of anti-cancer drug induced apoptosis involves other cellular mechanisms compared to Fas induced apoptosis. One could speculate that distinct NF-kB target genes are responsible for the modulation of particular pathways linked to either one of the apoptotic stimuli. Recently, a divergent apoptotic responsiveness to anti-cancer drugs and to TNFa has been attributed to the Bcl-2 family member A1/B¯-1 (Wang et al., 1999b) . The time pattern of NF-kB dependent gene expression may also contribute to the cellular outcome whether or not resistance to apoptosis is attained.
In addition, the strong basal activity of NF-kB in those cells being refractory to VP16 and doxorubicin may in¯uence not only the expression of particular anti-apoptotic genes but may also constitutively modulate chromatin function (Widlak et al., 1997; Sheppard et al., 1999 ) ± a property recently described for p53. Independently of its action as transcription factor, p53 regulates gene expression by modifying histone acetylation (Murphy et al., 1999) , hereby aecting the activation dynamics of silenced euchromatin. In particular, the constitutive presence of p50/ p50 homodimers observed in Capan-1 and A818-4 cells might modulate not only NF-kB (mainly p65/p50) dependent gene expression, as p50/p50 homodimers lack transcriptional activity, but also the functional dynamics of euchromatin (Salminen et al., 1998; Dechend et al., 1999) . Hereby, the balance in expression of pro-apoptotic and anti-apoptotic genes might be modi®ed in these cells thus favoring their survival from chemotherapeutic treatment.
In summary, selective inhibition of constitutive NFkB activity renders pancreatic cancer cell lines more sensitive to chemotherapeutic drugs, i.e. VP16 and doxorubicin. New strategies for combined chemotherapy of pancreatic tumors should be designed where speci®c blockade of NF-kB signi®cantly reduces the number of resistant cells (Jeremias et al., 1998; McDade et al., 1999; Wang et al., 1996) , and thus the rate of relapses.
Materials and methods
Materials and cell lines
The human pancreatic carcinoma cell lines A818-4, PT45-P1, BxPC-3 and Capan-1, as well as their handling were described previously (Kaltho et al., 1993) . The expression vector for the IkBa super-repressor (pcDNA6-DNIkBa) was kindly provided by Dr F Emmerich from the MaxDelbrueck-Centre for Molecular Medicine, Berlin. Routinely, subcon¯uent A818-4, PT45-P1, BxPC-3 and Capan-1 cells were kept in culture (378C, 5% CO 2 , 85% humidity) in RPMI 40 (1% glutamine, 10% fetal calf serum). TNFa, VP16, doxorubucin and sulfasalazine were from SIGMA (Deisenhofen, Germany), gliotoxin and IL-1b was from Calbiochem (Bad Soden/Ts, Germany) and MG132 from Biomol (Hamburg, Germany).
Electrophoretic mobility shift assay
For gel-shift assays, nuclear extracts were prepared as described recently (SchaÈ fer et al., 1998) and incubated with a g 32 P-labeled oligonucleotide 5'-AGTTGAGGG-GACTTTCCCAGGC-3' containing a consensus NF-kB binding site or the consensus AP-1 oligonucleotide 5'-CGCTTGATGAGTCAGCCGGAA-3' (Promega; Mannheim, Germany). After 30 min incubation at room temperature, samples were electropherized at 100 V, 48C. Gels were dried and exposed to X-ray Hyper®lm (Amersham; Freiburg, Germany). For NF-kB supershift assay, anti p65/ p50 NF-kB antibodies (Santa Cruz; Heidelberg, Germany) were added (1 h, 48C).
Western blotting
Cells were lyzed in 26SDS ± PAGE sample buer, heated (958C) for 5 min and submitted to 7.5% SDS ± PAGE. Upon electroblotting onto PVDF membrane, blots were blocked overnight with 5% non-fat milk powder, 0.1% Tween20 in PBS (blocking solution) at 48C. Afterwards, blots were exposed to a monoclonal antibody against PARP-1 (New England Biolabs) or to IkBa (Santa Cruz) at a 1000-fold dilution in blocking solution (30 min, room temperature). After extensive washing with blocking solution, blots were exposed to the appropriate second antibody and developed using the Phototope immunoblot detection kit (New England Biolabs).
Cell transfection and luciferase assay
Semicon¯uent cells grown on 6-well dishes were serum starved for 2 h and then submitted to lipofection (12 ml per well Eectene, Qiagen) using 0.3 mg pNF-kB-Luc or pAP-1-Luc (Stratagene) together with 0.2 mg pCMV-lacZ. After 16 h, medium was replaced and transfectants were further incubated for 6 ± 8 h. For cell lysis and detection of luciferase activity, a commercial assay kit (Promega; Mannheim, Germany) was used, and luciferase activity was quanti®ed in a Berthold luminometer. Similarly, cells were lipofected with 0.2 mg/well of an expression plasmid (pCDNA6) encoding DN-IkBa together with 0.2 mg/well pCMV-lacZ or with pCMV-lacZ alone. Transfection ecacy was checked by determination of lacZ expression using a commercial Gal ELISA (Boehringer; Mannheim, Germany).
FITC-AnnexinV/PI apoptosis assay
Upon treatment, 10 5 cells were harvested and resuspended in 200 ml of HEPES-buered saline. Then 10 ml of FITC-labeled enhanced-annexinV (ApoAlert, Clontech) and 100 ng of propidium iodide were added. Upon incubation in the dark (15 min, room temperature), samples were diluted with 0.5 ml PBS. Flow cytometry was carried out on a FACScan instrument (Becton Dickinson) and data were processed by WinMDI/PC-software. Those cells exhibiting high staining with Annexin V were regarded as being apoptotic.
Abbreviations FITC,¯uorescein isothiocyanate; IKK, IkB kinase; NFkB, nuclear factor kB; PVDF, polyvinylidene di¯uoride.
